Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma

[Image: see text] BTK is a member of the TEC family of non-receptor tyrosine kinases whose deregulation has been implicated in a variety of B-cell-related diseases. We have used structure-based drug design in conjunction with kinome profiling and cellular assays to develop a potent, selective, and irreversible BTK kinase inhibitor, QL47, which covalently modifies Cys481. QL47 inhibits BTK kinase activity with an IC(50) of 7 nM, inhibits autophosphorylation of BTK on Tyr223 in cells with an EC(50) of 475 nM, and inhibits phosphorylation of a downstream effector PLCγ2 (Tyr759) with an EC(50) of 318 nM. In Ramos cells QL47 induces a G1 cell cycle arrest that is associated with pronounced degradation of BTK protein. QL47 inhibits the proliferation of B-cell lymphoma cancer cell lines at submicromolar concentrations.